c-MET

KRC-00715 is a potent oral inhibitor of c-Met with an IC50 of 9.0 nM, exhibiting high selectivity for gastric cancer cells. This compound effectively induces G1/S phase arrest in c-Met-overexpressing cell lines, resulting in diminished downstream signaling through Akt and Erk pathways as well as reduced c-Met activity. In the gastric cancer cell line Hs746, KRC-00715 demonstrates an IC50 of 39 nM and shows significant efficacy in reducing tumor size in Hs746T xenograft mouse models, highlighting its potential application in cancer research and therapeutics.

SOMCL-863 is a selective and orally bioavailable c-Met inhibitor, demonstrating significant antitumor activity in both in vitro and in vivo models. This compound serves as a valuable tool in cancer research, aiding in the exploration of pathways involving c-Met and its role in tumor progression.

EMD 1204831 is a potent and selective inhibitor of the c-Met receptor tyrosine kinase, exhibiting an IC50 of 9 nM. This compound effectively suppresses c-Met activity, making it a valuable tool for investigating the role of c-Met in cancer biology. Its application can lead to insights into tumor growth, metastasis, and potential therapeutic strategies targeting c-Met dysregulation.

T-1840383 is a highly potent ATP-competitive inhibitor targeting c-Met and VEGFR-2, demonstrating IC50 values of 1.9 nM for c-Met, 7.7 nM for VEGFR1, 2.2 nM for VEGFR2, and 5.5 nM for VEGFR3. This compound effectively inhibits key signaling pathways associated with cancer progression and angiogenesis. It is suitable for research applications focused on tumor growth and vascular development, making it a valuable tool in oncology and vascular biology studies.

LCRF-0004 is a potent inhibitor of RON kinase, exhibiting an IC50 value of 10 nM. Additionally, LCRF-0004 also demonstrates significant inhibitory activity against c-Met, with an IC50 of 12 nM. This compound is valuable for research in cancer biology, particularly in studies focusing on RON kinase and c-Met signaling pathways.